BeBetter Med (688759) Stock Overview

A biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. More details

688759 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 65.1% below our estimate of its fair value

Revenue is forecast to grow 117.16% per year

Risk Analysis

Makes less than USD$1m in revenue (CN¥0)

Earnings are forecast to decline by an average of 1.6% per year for the next 3 years

Volatile share price over the past 3 months compared to the CN market

Currently unprofitable and not forecast to become profitable over the next 3 years

688759 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW465,688 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

465,688 investors already sharing narratives

View all narratives

BeBetter Med Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BeBetter Med
Historical stock prices
Current Share Price	CN¥26.70
52 Week High	CN¥57.47
52 Week Low	CN¥20.70
Beta	0
1 Month Change	-25.73%
3 Month Change	-27.27%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-13.90%

Recent updates

Shareholder Returns

	688759	CN Biotechs	CN Market
7D	-5.2%	-0.7%	-1.5%
1Y	n/a	-23.1%	4.0%

Return vs Industry: Insufficient data to determine how 688759 performed against the CN Biotechs industry.

Return vs Market: Insufficient data to determine how 688759 performed against the CN Market.

Price Volatility

Is 688759's price volatile compared to industry and market?
688759 volatility
688759 Average Weekly Movement	11.1%
Biotechs Industry Average Movement	7.9%
Market Average Movement	7.3%
10% most volatile stocks in CN Market	12.5%
10% least volatile stocks in CN Market	4.4%

Stable Share Price: 688759's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 688759's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

Founded	Employees	CEO	Website
2012	160	Changgeng Qian	www.bebettermed.cn

BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases. It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC. The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash; BEBT-507, a GalNAc-siRNA drug for Polycythemia Vera (PV); and BEBT-701, a GalNAc-siRNA therapeutic for treatment of hypertension with co-existing hyperlipidemia.

BeBetter Med Inc. Fundamentals Summary

How do BeBetter Med's earnings and revenue compare to its market cap?
688759 fundamental statistics
Market cap	CN¥12.02b
Earnings (TTM)	-CN¥170.50m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-70.5x

P/E Ratio

Is 688759 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688759 income statement (TTM)
Revenue	CN¥0
Cost of Revenue	CN¥0
Gross Profit	CN¥0
Other Expenses	CN¥170.50m
Earnings	-CN¥170.50m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-0.38
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 688759 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/22 21:53
End of Day Share Price	2026/08/21 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BeBetter Med Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bing Zhao	China Renaissance Securities

BeBetter Med Inc.SHSE:688759 Stock Report